A health care programme's economic efficiency can be described in terms of its cost effectiveness ratio, defined as the net cost per unit of health outcome. The most useful health outcome units for comparisons of the efficiency of programmes are the life year saved and the quality adjusted life year (QALY) saved, but intermediate outcomes, such as the number of cases of disease detected or admissions to hospital avoided can also be used. In view of current interest in allocation of health care resources to programmes on the basis of economic efficiency,' accurate assessment of the cost effectiveness of treatment and disease prevention programmes is important. Calculation of a cost effectiveness ratio involves identification and measurement of both the immediate and consequential health care costs (and savings) associated with a programme, and, similarly, measurement of the programme's short and long term effects on the specified health outcome 1989 . These aimed to study the costs of mammographic screening, the acceptability of screening to Australian women (as measured by attendance rates), and standards of service delivery (as measured by recall rates, surgical biopsy rates, and the positive predictive value of screening).
The study described in this paper was conducted within the state of Victoria's pilot project, the Essendon Breast X ray Programme. Other studies relating to the cost effectiveness of recruitment activities,8 and the personal costs incurred by women attending the programme,9 have been reported. The programme was a joint venture of the Royal Melbourne Hospital (RMH) and the Anti-Cancer Council of Victoria (ACCV), with RMH responsible for screening, assessment and day to day management, and the ACCV responsible for recruitment, data management, evaluation, and research. The service was located at the Essendon Hospital (a campus of the RMH) and ran for two years, from November 1988 to October 1990. It offered mammographic screening to women aged 50-69 years living in any of 34 postcode areas. Free consequential assessment, apart from surgical biopsy, for women with abnormal mammograms was also provided.
The electoral roll, which includes approximately 85% of the Victorian population,'0 was chosen as the programme's population list, in order to recruit women and measure attendance rates. There were 43836 women aged 50-69 years living in the target area who were listed on the electoral roll. Although women who were not on the electoral roll were allowed to attend, they were neither actively recruited nor included in calculations of attendance rates.
Both public and personal recruitment campaigns were used to encourage women to attend the programme.8 The public recruitment campaign consisted of local newspaper articles, community promotion (displays of motivational material in shops and public places, appointment stalls at shopping centres, and personal contact with community and workplace organisations) and promotion of the programme to general practitioners. The personal recruitment campaign comprised invitation letters to randomly selected women on the programme's population list. Women who did not attend or make an appointment in response to the first letter within four weeks were often sent a follow up letter, and a small sample of women were allocated to telephone follow up.
The programme operated according to a protocol illustrated in figure 1. Screening was only available by appointment. All women had twoview mammography (a medio-lateral oblique projection and a cranio-caudal projection). The programme had two mammography units, and films were developed using a dedicated processor, before the woman left the programme. Women who reported either a breast lump or bleeding from the nipple were referred for clinical assessment, irrespective of the mammography findings. Mammograms were read independently by two Our study was conducted in two phases. Firstly, unit costs for each component of the screening process, each activity contributing to clinical assessment, and surgical biopsy were estimated. The costs for services provided by the programme were based on expenditures, resource usage, and outputs during the first 12 months of operation. Opportunity costs derived from a number of sources were used to value the services associated with surgical biopsy.
In the second phase, the cost per woman screened, and the cost per case of breast cancer detected were estimated by determining the outcomes for the cohort of eligible women who were screened during the first 12 months. Women were considered eligible if they were aged 50-69 years at screening, lived in the target area, were listed on the electoral roll, and had no history of breast cancer. A record of diagnostic procedures was constructed for eligible women who were referred to clinical assessment, including information on services related to surgical biopsy provided externally. Costs were classified as either recurrent, capital, or establishment. Recurrent costs were the costs of operating the programme, and were further classified into four groups-staff, advertising, miscellaneous, and overheads. Staff costs comprised salaries for the 11 full time equivalent (FTE) staff paid through the programme budget (a director (0-1 FTE), a radiologist (0-5FTE), radiographers (1) (2) (3) (4) (5) (6) (7) (8) , and a full time manager, counsellor, receptionist, clerk, data entry clerk, state enrolled nurse, education officer, research assistant and project officer) plus salaries for the time spent by additional RMH staff (06-1 0 FTE) and ACCV staff (0-5FTE) who worked on the programme. Advertising costs (for promotional materials) were apportioned equally to months over the periods between reordering supplies. Miscellaneous costs included consumables (film, postage, stationery, telephone), costs for recruitment related travel, and the portions of the costs of ultrasound examinations and cytological examination of fine needle biopsy aspirates which were incurred outside the programme valued according to Medicare (the national health insurance scheme) fees.
Overhead costs related both to the RMH and ACCV. The programme's RMH overheads consisted of administrative costs; an estimated The probabilities of progression between phases of the screening pathway were calculated for all eligible women who were screened in the first 12 months. Management details for women referred for clinical assessment were obtained from the database and from women's medical histories at centres where the surgical biopsy was performed. In some instances, surgical biopsy was the only surgical treatment a woman received, and it was therefore difficult to know whether to regard the biopsy as diagnostic or therapeutic. For this study, we classified services used prior to definitive surgery as diagnostic, and services used during and after admission to hospital for definitive surgery as therapeutic. Therefore, if a woman had a provisional diagnosis of breast cancer on the basis of FNA biopsy at the programme and was then referred for a surgical biopsy which was definitive, the surgery was regarded as therapeutic, and costs were not included as diagnostic costs.
The cost per woman screened was then calculated by summing the products of the cost of each phase of the screening process and the probability that a woman progressed to that phase. In other words: cost per woman screened= recruitment cost + screening cost + (recall mammography cost) x probability that a woman was referred to recall mammography) + (clinical assessment cost) x (probability that a woman was referred to clinical assessment).
The cost per cancer detected was calculated by dividing the cost per woman screened by the probability of diagnosing cancer in a screened woman.
Results

UNIT COSTS
The total costs for each of the eight cost centres for the 12 month period are summarised, by expenditure category, in table 1. The table indicates that screening was by far the largest cost centre. A total of $193 577 for administration, evaluation and training was then reallocated to screening, recall mammography and clinical assessment. The $26 625 initially allocated to research was not reallocated to service cost centres. The number of women seen at each phase of screening, and the estimated unit costs for recruitment, screening, recall mammography, and clinical assessment are summarised for each quarterly period and the total period in table 2. The unit costs for clinical assessment were the programme based costs per woman referred for clinical assessment, and in many instances related to more than one visit. For recruitment and screening, the unit costs for the second and third quarters were lower than the first and fourth quarters, but a strong trend towards decreasing unit costs over time was not evident. However, for recall mammography and clinical assessment, unit costs were substantially lower in the third and fourth quarters, when throughput was greater, compared with the first two quarters.
A sensitivity analysis was undertaken by omitting ACCV overheads, on the basis that the programme could possibly have been administered solely by RMH for the same overhead cost. This reduced the unit costs for recruitment, screening, recall mammography, and creased the cost per woman by only 3 1 %, and a 10% increase in diagnosis costs for women with breast cancer increased the cost per woman screened by only 0 4%. A decrease in the cancer detection rate to 7 per 1000 women would increase the cost per cancer detected to around $16 800.
Discussion
Our study yielded estimates of the unit costs of each phase of the screening process, the cost per woman screened, and the cost per cancer detected for the first 12 months of operation of a pilot, population based mammographic screening programme. This discussion will focus on the validity of the methods used to obtain these estimates, the projected variations in costs with changing throughput, and the implications of these costs for implementation of mammographic screening services. Three practical difficulties arise in costing health care: tracking resource usage, apportioning joint resource usage to the appropriate activity, and valuing resources credibly. These problems were minimised in this study because the programme was newly established, and evaluation of costs was an objective from the outset. Hence, accounting systems were established to facilitate economic evaluation and staff were receptive to recording activities. Resource usage was fairly simple to monitor within the programme. However, considerable effort was required to obtain details of management of women referred from the programme for further assessment.
The issue of apportioning joint resource usage to individual activities arose in two ways. Firstly, within the programme, staff, film, and consumables were used for a number of different activities, and apportionment of costs to cost centres was determined through surveys and database records. This apportionment had a potentially big impact on unit costs. Staff costs comprised 54% of total costs (table 3) and were allocated on the basis of activity surveys conducted over 10 working days. As staff performed different activities each day, depending, for example, on whether screening or recall clinics were offered, it was important to obtain measurements of activities on each day of the week and to then determine the proportion of each staff member's time devoted to the defined cost centres. Activity diaries, which were simple and acceptable to staff, were used, but involved possible inaccurate recording of information, either inadvertently due to the response burden, or, purposefully due to concerns about the survey. The response burden was minimised by having staff complete the diaries for only one day in any week, and concerns were allayed by involving staff in design of the survey. Other methods for work analysis were considered, including continuous observation, whereby an observer measures the time spent by staff on predetermined categories of activities, and work sampling, which involves an observer recording multiple observations of a staff member's activities at randomly selected times. ' It could be argued that the cost per woman screened of $117 70, derived on the basis of the first 12 months of screening, represented a start up phase, and that costs would drop once the programme was operating at full capacity. In fact, more than 80%, and often more than 90% of available appointments were filled almost every week from the fourth month onwards. The number of radiographers was considered to be the main constraint on screening capacity and therefore the radiographer establishment was increased from 1 8 FTE to 3 0 FTE in February 1990. Over the next six months (February-July 1990), 5638 women were screened, and assessed when indicated. This was 1598 women more than the number screened during the final two quarters of the first 12 months. Complete cost and outcome data were not available for this period. However, approximately $27 000 was spent on the additional radiographer staff and x ray film required to screen these extra women. Assuming that all other costs remained constant, the unit cost of screening for this six month period would be approximately $42 50-approximately a 30% decrease compared with the figure for the first 12 months. Only 8 3% of women screened over the six month period February to July 1990 were recalled for further mammography. If it is assumed that unit recruitment and diagnosis costs and cancer detection rates were unchanged, the cost per woman screened would be approximately $96 96, an 18% reduction compared with the first year. Programme staff believed that it was extremely unlikely that screening capacity could be increased any further. The only opportunity for further increasing throughput would be a decrease in recall rates, which would make more screening sessions available. The only opportunity for reducing staff costs, which comprised 53% of total costs, was thought to be reduction in the number of hours worked by the counsellor, as it was thought that her availability for screening sessions was not warranted. However, this would have a negligible impact on screening costs.
Although changes in the cancer detection rate would only have a small impact on the cost per woman screened, they would have a big effect on the cost per cancer detected. The cancer detection rate for the first 12 months of the programme was 10 2 per 1000 women screened. This rate is substantially higher than the maximum cancer detection rate of 7 
